Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

673 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Dose escalation and expansion phase I studies with the tumour-targeting antibody-tumour necrosis factor fusion protein L19TNF plus doxorubicin in patients with advanced tumours, including sarcomas.
Schliemann C, Hemmerle T, Berdel AF, Angenendt L, Kerkhoff A, Hering JP, Heindel W, Hartmann W, Wardelmann E, Chawla SP, de Braud F, Lenz G, Neri D, Kessler T, Berdel WE. Schliemann C, et al. Among authors: de braud f. Eur J Cancer. 2021 Jun;150:143-154. doi: 10.1016/j.ejca.2021.03.038. Epub 2021 Apr 23. Eur J Cancer. 2021. PMID: 33901793 Clinical Trial.
Lanreotide autogel every 6 weeks compared with Lanreotide microparticles every 3 weeks in patients with well differentiated neuroendocrine tumors: a Phase III Study.
Bajetta E, Procopio G, Catena L, Martinetti A, De Dosso S, Ricci S, Lecchi AS, Boscani PF, Iacobelli S, Carteni G, De Braud F, Loli P, Tartaglia A, Bajetta R, Ferrari L. Bajetta E, et al. Among authors: de dosso s, de braud f. Cancer. 2006 Nov 15;107(10):2474-81. doi: 10.1002/cncr.22272. Cancer. 2006. PMID: 17054107 Free article. Clinical Trial.
Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer.
Sessa C, Perotti A, Noberasco C, De Braud F, Gallerani E, Cresta S, Zucchetti M, Viganò L, Locatelli A, Jimeno J, Feilchenfeldt JW, D'Incalci M, Capri G, Ielmini N, Gianni L. Sessa C, et al. Among authors: de braud f. Eur J Cancer. 2009 May;45(7):1153-1161. doi: 10.1016/j.ejca.2008.11.019. Epub 2008 Dec 27. Eur J Cancer. 2009. PMID: 19114300 Clinical Trial.
Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
Sessa C, Cresta S, Noberasco C, Capri G, Gallerani E, De Braud F, Zucchetti M, D'Incalci M, Locatelli A, Marsoni S, Corradino I, Minoia C, Zintl P, Gianni L. Sessa C, et al. Among authors: de braud f. Eur J Cancer. 2009 Aug;45(12):2116-22. doi: 10.1016/j.ejca.2009.04.002. Epub 2009 May 4. Eur J Cancer. 2009. PMID: 19419856 Clinical Trial.
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma.
Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, Miller K, Berndt A, Kosmehl H, Trachsel E, Kaspar M, Lovato V, González-Iglesias R, Giovannoni L, Menssen HD, Neri D, de Braud F. Johannsen M, et al. Among authors: de braud f. Eur J Cancer. 2010 Nov;46(16):2926-35. doi: 10.1016/j.ejca.2010.07.033. Epub 2010 Aug 24. Eur J Cancer. 2010. PMID: 20797845 Clinical Trial.
A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.
Eigentler TK, Weide B, de Braud F, Spitaleri G, Romanini A, Pflugfelder A, González-Iglesias R, Tasciotti A, Giovannoni L, Schwager K, Lovato V, Kaspar M, Trachsel E, Menssen HD, Neri D, Garbe C. Eigentler TK, et al. Among authors: de braud f. Clin Cancer Res. 2011 Dec 15;17(24):7732-42. doi: 10.1158/1078-0432.CCR-11-1203. Epub 2011 Oct 25. Clin Cancer Res. 2011. PMID: 22028492 Clinical Trial.
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma.
Gallerani E, Zucchetti M, Brunelli D, Marangon E, Noberasco C, Hess D, Delmonte A, Martinelli G, Böhm S, Driessen C, De Braud F, Marsoni S, Cereda R, Sala F, D'Incalci M, Sessa C. Gallerani E, et al. Among authors: de braud f. Eur J Cancer. 2013 Jan;49(2):290-6. doi: 10.1016/j.ejca.2012.09.009. Epub 2012 Oct 8. Eur J Cancer. 2013. PMID: 23058787 Review.
Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours.
Spitaleri G, Berardi R, Pierantoni C, De Pas T, Noberasco C, Libbra C, González-Iglesias R, Giovannoni L, Tasciotti A, Neri D, Menssen HD, de Braud F. Spitaleri G, et al. Among authors: de pas t, de braud f. J Cancer Res Clin Oncol. 2013 Mar;139(3):447-55. doi: 10.1007/s00432-012-1327-7. Epub 2012 Nov 17. J Cancer Res Clin Oncol. 2013. PMID: 23160853 Clinical Trial.
673 results